Medovate and Mercury strike SAFIRA distribution deal

Medovate has entered into an agreement with Mercury Medical for exclusive distribution of the FDA-cleared device SAFIRA (SAFer Injection for Regional Anaesthesia) across the whole of the United States.  

The agreement also includes the newly launched SAFIRA Palm Operator which has been launched in the US market to offer anaesthesiologists more versatility and choice when using the SAFIRA regional anaesthesia system.   

Stuart Thomson, managing director of Medovate, said: “As our company grows, it has been our vision to centralise our USA distribution with a primary distributor to streamline processes and provide a single contact point for clinicians in the US interested in SAFIRA. Mercury Medical have positioned themselves as a US leader in providing technological advances for clinicians in both airway solutions and anaesthesia – a philosophy that aligns very well with Medovate and SAFIRA. We are excited to this partnership with them as primary distributor of our SAFIRA system in the USA and look forward to entering this next phase of our journey.”